Inovio's lead DNA medicine INO-3107 targets respiratory disease with FDA review due by Oct 30.

Inovio Pharmaceuticals, a clinical-stage biotech company, is advancing its lead DNA medicine, INO-3107, for treating Recurrent Respiratory Papillomatosis (RRP). The drug is currently under FDA review through the accelerated approval program, with a target decision date of October 30, 2026. This development is significant as it could provide a new treatment option for HPV-related respiratory diseases. CEO Jacqueline Shea highlighted the company's focus on DNA medicines for infectious diseases and cancers during the H.C. Wainwright 28th Annual Global Investment Conference.